ND1: INDIRECT COSTS DUE TO BACK PAIN IN THE UNITED STATES  by Mychaskiw, MA & Thomas, J
416 Abstracts
persons aged 20 to 34 years, 1.0% had used sleeping
medication and among those aged 75 to 84 years 16.1%
did. Use of sleeping medication was more common among
women (5.3%) compared to men (3.0%). Individuals with
sleeping problems scored significantly lower (p  .05) than
those without sleeping problems on all of the eight do-
mains in SF-36  RE  20.3; VT  19.3; MH  16.8;
GH  16.2; SF  15.6; RP  15.1; BP  13.4 and PF 
7.9. Among individuals with sleeping problems, those us-
ing sleeping medication scored lower on seven domains
of the SF-36  RE  10.5; MH  10.4; SF  8.8; GH 
8.1; BP  7.8; VT  6.1 and PF  5.8.
CONCLUSION: Sleeping problems are common in the
population and lead to a significantly decreased quality
of life among affected individuals.
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OBJECTIVE: Depression is a common recurrent disease.
Usually, each successive episode of depression is more
difficult to cure. The objective of this study is to assess
costs, methods of treatment, and outcomes of the first ep-
isode of depression compared to the second and subse-
quent episodes.
METHODS: Study was designed as a one-year prospec-
tive, natural observation. Psychiatrists who took part in
this trial recruited one patient with a first episode of de-
pression, one with a second episode after a period of re-
mission and one with a third or next episode after a pe-
riod of remission. During the study, carried out in 1999
with three months tolerance, data concerning treatment
methods, their outcomes, changes in health state, and
economic and social consequences of depression were
collected. A social perspective was applied. The capital
cost method was used for indirect costs.
RESULTS: Five hundred thirty two patients were in-
cluded, and 94% of them were followed to the end of the
study (one-year observation). The average direct medical
cost per patient with a first episode of depression was
2097 PLN (1 Euro  3.50 PLN), with a second was 2241
PLN and with a third and the following 3357 PLN. Di-
rect medical costs included: the cost of hospitalization
(49%); doctors consultations (29%); non-pharmacologi-
cal treatment (14%); pharmacological treatment (8%);
laboratory and diagnostic tests (1%). Indirect costs per
patient with a first episode reached 10,834 PLN, with a
second, 13,802 PLN, and with a third and following,
15,012 PLN. The distribution of indirect cost was as fol-
lows: sick leaves 40.5%, sickness pensions 59%, and sui-
cides 0.5%. Total costs in the three study groups were
12,931 PLN, 16,043 PLN and 18,369 PLN respectively.
CONCLUSIONS: Treatment of a third episode of de-
pression costs 60% more than the first episode. Direct
medical costs account for only 16% of total costs.
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OBJECTIVE: Schizophrenia is probably one of the most
costly mental-health illnesses in terms of its impact on the
society, on the health-care system and on patients and
their families. We aim to develop a framework for ana-
lyzing schizophrenia through the estimation of the costs
of illness as well as the costs of relapse in the manage-
ment of schizophrenia in a UK care setting.
METHODS: A model that utilizes a Markov structure was
elaborated in order to calculate the lifetime cost of illness
and the principal cost driver in schizophrenia, the cost of
relapse. The model included the main confounding factors
such as compliance, dropout, and treatment location,
which have been shown to be important in the literature
when constructing a model. The costs were estimated for a
10-year period as well as for the lifetime of a patient, and
consider all types of treatment structures in the UK.
RESULTS: The average 10-year cost of illness for a patient
in a UK treating environment was estimated at £ 66 600,
and the lifetime cost per patient at £ 98 510. As for the cost
of relapse of a schizophrenic patient, the 10-year cost was
£ 51 630 and the lifetime cost per patient was £ 75 890.
CONCLUSIONS: This model enables the identification
and the calculation of the main cost drivers in the treat-
ment of schizophrenia. This model can therefore be used
to evaluate the cost implication of treatment options and
policy choices, by generating budgetary provisions. Hence,
this model can help decision-makers in policy-making for
mental health-care organizations in the management of
schizophrenia.
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OBJECTIVE: Back pain is a leading cause of absence and
disability in the workplace. Costs associated with lost
productivity due to back pain are significant and may be
as high as the costs of medical care for this condition.
However, there has been limited study of the indirect
costs of back pain in the United States. The objective of
this study was to determine the indirect costs due to back
pain in the US population.
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METHODS: A retrospective analysis of the 1996 portion
of the Medical Expenditure Panel Survey (MEPS) was
conducted. The MEPS provided data from a nationally
representative sample of 22,601 respondents and data
from respondent’s medical care and health-insurance
providers and employers. Data included medical condi-
tions and employment information comprised of hourly
earnings, hours worked, and disability days. Back pain
patients who incurred disability days were identified us-
ing International Classification of Diseases (ICD-9-CM)
codes determined by an expert panel of physicians and
coders as indicative of back pain and variables denoting
disability days. Indirect costs were calculated for back
pain patients who missed workdays using the human
capital approach. Sample estimates were weighted and
projected to the population and 95 percent confidence in-
tervals for estimates were calculated using the Taylor ex-
pansion method.
RESULTS: Total indirect costs for back pain patients
who missed workdays were $18,533,583,620. Mean in-
direct costs were $4586 per back pain patient who
missed workdays (95% CI  $3852 to $5321). Relative
to the entire population, the mean indirect costs were
$68.92 per person.
CONCLUSIONS: With losses in productivity greater than
$18.5 billion, indirect costs significantly contribute to the
total cost of back pain. The indirect costs of back pain to
labor underscore the need to prevent back injury thereby
promoting employee health and maintaining productivity.
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OBJECTIVES: To assess the influence of depression, de-
mentia and disease severity on the health-related quality
of life in Parkinson’s disease (PD).
METHODS: Health-related quality of life was assessed
in 91 patients with PD (male: 62; female: 29; mean age:
67  9) using the Parkinson’s disease questionnaire
(PDQ-39) and the Parkinson’s disease Quality of life
questionnaire (PDQL). Dementia was evaluated by using
the MMSE and depression was rated with the Beck’s De-
pression Inventory (BDI). Disease severity and motor dys-
function were recorded with the Hoehn and Yahr scale
and the UPDRS II-IV. Pearson’s correlation coefficient
was used to calculate correlation scores.
RESULTS: Both specific disease QoL rating scales corre-
lated with depressive symptoms (r  0.73, p  .0001).
UPDRS III (r  0.69, p  .0001) and HY stage (r  0.59,
p  .001) also correlated with decreased QoL. However,
motor fluctuations and dyskinesias had a minor impact
on QoL (r  0.40, p  .001). Dementia or cognitive im-
pairment had a minor correlation with QoL (r  0.30, p 
.001).
CONCLUSIONS: We found a high correlation between
QoL and depression by using PDQ-39 and PDQL. In
contrast, a minor correlation was observed between
MMSE scores and health-related QoL. Treating depres-
sive symptoms in PD patients may considerably improve
their quality of life.
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OBJECTIVE: 25% to 30% of patients with Parkinson’s
disease treated with levodopa present motor complica-
tions after three years. The health-care consumption by
patients with these symptoms is roughly twice as high as
the costs for patients without them. A clinical trial com-
paring cabergoline (with the possibility if adding levodopa
if needed) to levodopa has shown that the use of caber-
goline delays the onset of motor complications. The pur-
pose of this study is to compare the cost-effectiveness of
the two treatment strategies in a Swedish setting.
METHODS: A Markov model was constructed with
states based on the Hoehn and Yahr (HY) stages with an
additional stage for patients with complications. Transi-
tion probabilities between the HY stages were calculated
from the clinical trial data using ordered probit regres-
sion, while the probability of developing complications
was based on the frequency of this event at each time
point in the trial. Direct costs were derived from a Swed-
ish observational study. Years-of-complications-avoided
was used as the measure of effectiveness in this analysis.
RESULTS: The incremental cost-effectiveness ratio for
cabergoline was 4000 USD per year of motor complica-
tions avoided. Inclusion of indirect costs would influence
the results in younger patients. The literature suggests
that the costs of indirect care would decrease the cost-ef-
fectiveness ratio, so that the number reported here may
represent an overestimate of the total cost of preventing
motor complications.
CONCLUSION: Based on our data, Cabergoline was
found to represent a cost-effective means for reducing the
impact of motor dysfunction if the willingness to pay ex-
ceeds 4000 USD per year of motor complications avoided.
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